Professional organizations rarely contradict themselves in public. When they do, the contradiction is usually buried in procedural language, masked by committee structure, or softened by the slow drift of policy. But occasionally, the inconsistency becomes visible in plain sight, not because someone exposed it, but because two arms of the same organization published incompatible statements without noticing. That is what happened when the American Academy of Pediatrics (AAP) reaffirmed its 2020 autism clinical report in October 2025, two years after its own legal team filed an amicus brief condemning aversive practices at the Judge Rotenberg Center.

The amicus brief was clear, forceful, and ethically unambiguous. It stated that contingent electric shock, used as punishment for autistic individuals, was dangerous, lacked scientific justification, and violated pediatric ethical standards. The FDA reached the same conclusion in 2020 when it banned the devices, calling them unsafe and medically indefensible. That ban was overturned not because the science changed, but because of a narrow technicality about regulatory authority. The underlying judgment remained intact: These practices should not exist.

The AAP’s legal staff understood this. They wrote it plainly. They told the truth. The scientific committee did not.

In October 2025, the AAP reaffirmed its 2020 autism guideline, unchanged, unamended, and still endorsing applied behavior analysis (ABA) as first-line therapy without acknowledging its aversive lineage or the federal determination that its most extreme form was unethical. The reaffirmation did not mention the amicus brief. It did not mention the FDA ban. It did not mention the ethical contradiction. It simply preserved the original language, as though nothing had happened.

This is not a minor oversight. It is an institutional disconnect with ethical consequences.

If the AAP’s legal team had cited the 2020 guideline in its amicus brief, the court could have dismissed the filing outright. Courts do not accept contradictory expert testimony. A brief that condemns aversive practices cannot simultaneously rely on a guideline that endorses the therapy from which those practices emerged. The inconsistency would have been fatal. The brief would have been thrown out. The only reason the contradiction did not undermine the legal filing is that the legal team did its job and the scientific committee did not.

This kind of internal inconsistency is not new in medicine. It resembles the “Comey 8657” problem, a case in which an institution’s public statements contradicted its internal findings, creating a structural inconsistency that was visible only to those who examined both documents side by side. The problem was not malice. It was institutional drift: One arm of the organization moved forward while another remained anchored to outdated language.

That is what happened here. The AAP’s legal staff confronted the ethical reality of aversive practices. The scientific committee reaffirmed a document that ignored it. The result is a published contradiction.

The reaffirmation matters because guidelines shape practice. They influence insurance coverage, state policy, training programs, and clinical expectations. When a guideline endorses a therapy without acknowledging its ethical failures, it signals to clinicians that the therapy is unproblematic. When the same organization’s legal team tells a federal court that the therapy’s most extreme form is dangerous and unethical, it signals the opposite. Both statements cannot be true.

The contradiction also matters because it reveals how institutional structures can fail. The legal team read the evidence. The scientific committee did not read the legal team’s work. The reaffirmation process did not include an ethical review. The committee did not ask whether new information, including the organization’s own legal position, required revision. Instead, it preserved the status quo.

Reaffirmation after conscience is not neutrality. It is avoidance.

The deeper problem is that reaffirmation is often treated as a procedural act rather than a substantive one. Committees review documents for currency, formatting, and alignment with existing literature. They do not always review them for ethical consistency. They do not always ask whether the organization’s own actions, including legal filings, policy statements, or public testimony, require updating the scientific language. But they should. Especially when the contradiction is this stark.

The AAP’s amicus brief told the court that aversive practices violate pediatric ethics. The FDA told the country that these practices are unsafe and medically indefensible. The reaffirmed guideline told clinicians nothing about either. This is not simply an oversight. It is an ethical breach.

Guidelines must evolve when evidence evolves. They must evolve when ethics evolve. And they must evolve when the organization itself evolves. When the legal arm of a professional society declares a practice unethical, the scientific arm cannot simply reaffirm silence.

Reaffirmation is a choice. Silence is a choice. And choices have consequences.

The AAP now has two published positions: one that condemns aversive practices and one that ignores them. The contradiction is visible. It is documented. And it is fixable, but only if the organization acknowledges that reaffirmation is not a clerical act. It is an ethical one.

J’Accuse.

Ronald L. Lindsay is a retired developmental-behavioral pediatrician whose career spanned military medicine, academic leadership, and national advocacy for dignity-centered neurodevelopmental care. His NIH-funded work with the RUPP Autism Network helped define evidence-based approaches to autism and related developmental disorders.

He directed the LEND Program at The Ohio State University and founded JBLM CARES, a $10 million autism resource center for military families. His writing spans clinical scholarship and long-form fiction. He is the author of The Mercy Directive and the six-novel Cassandra series, a completed political and medical fiction saga tracing the rise of the Cassandra system from its origins to its national and international legacy. His forthcoming memoir, The Quiet Architect, examines how conscience and structure collide in modern medicine.

He shares updates on LinkedIn.